Loading...
Loading...
RNXT| Name | Value |
|---|---|
| Revenues | 422.0K |
| Cost of Revenue | 152.0K |
| Gross Profit | 270.0K |
| Operating Expense | 2,948.0K |
| Operating I/L | -2,678.0K |
| Other Income/Expense | -217.0K |
| Interest Income | 133.0K |
| Pretax | -2,895.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -2,895.0K |
RenovoRx, Inc. is a clinical-stage biopharmaceutical company specializing in developing therapies for solid tumors. Their lead product candidate, RenovoGem, is a drug and device combination undergoing Phase III clinical trials for locally advanced pancreatic cancer. The company generates revenue through the development and potential commercialization of RenovoGem, which consists of intra-arterial gemcitabine and RenovoCath. RenovoRx, Inc. aims to address the unmet medical needs in cancer treatment, positioning itself to capitalize on the market demand for innovative therapies targeting solid tumors.
